Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sarepta Therapeutics, Inc.SRPT · Entity 4426 | EVP, General Counsel | June 21, 2024 | June 26, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sarepta Therapeutics, Inc.
Report date June 21, 2024 · Filed June 26, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,129 |
Ending reported balance
After 2024-06-25 transaction · row 10
10 source rows · reconciled sequenceRow 1 · 2024-06-21 · Exercise / conversion · Acquired 6,250 · Balance 34,938 F1: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. Row 2 · 2024-06-24 · Tax withholding · Disposed 2,352 · Balance 32,586 F2: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of PSUs granted on March 1, 2024. Row 3 · 2024-06-25 · Exercise / conversion · Acquired 23,500 · Balance 56,086 Row 4 · 2024-06-25 · Sale · Disposed 7,644 · Balance 48,442 F3: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2024. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $157.58 to $158.52, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Row 5 · 2024-06-25 · Sale · Disposed 2,200 · Balance 46,242 F3: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2024. F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.67 to $159.66, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Row 6 · 2024-06-25 · Sale · Disposed 975 · Balance 45,267 F3: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2024. F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.71 to $160.69, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Row 7 · 2024-06-25 · Sale · Disposed 4,168 · Balance 41,099 F3: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2024. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $161.04 to $162.02, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Row 8 · 2024-06-25 · Sale · Disposed 17,581 · Balance 23,518 F3: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2024. F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $162.12 to $163.09, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Row 9 · 2024-06-25 · Sale · Disposed 3,840 · Balance 19,678 F3: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2024. F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.19 to $163.98 inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Row 10 · 2024-06-25 · Sale · Disposed 2,549 · Balance 17,129 F3: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2024. |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 5,500 |
Reported balance
After 2024-06-21 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2024-06-21 · Grant · Acquired 5,500 · Balance 5,500 F10: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 7, 2022. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 7, 2025, subject to the Reporting Person continuing to provide service to the Company through such vesting date. |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 6,250 |
Reported balance
After 2024-06-21 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2024-06-21 · Grant · Acquired 6,250 · Balance 6,250 F1: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. |
| Performance Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-06-21 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2024-06-21 · Exercise / conversion · Disposed 6,250 · Balance 0 F1: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $62.77 · Expires 2028-02-28 | Direct | 0 |
Reported balance
After 2024-06-25 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2024-06-25 · Exercise / conversion · Disposed 23,500 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU.
F2: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of PSUs granted on March 1, 2024.
F3: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2024.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $157.58 to $158.52, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.67 to $159.66, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.71 to $160.69, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $161.04 to $162.02, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $162.12 to $163.09, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.19 to $163.98 inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F10: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 7, 2022. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 7, 2025, subject to the Reporting Person continuing to provide service to the Company through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 25, 2024 Filed Jun 26, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock Option (right to buy) · Derivative | 23,500 | $0.00 Strike: $62.77 | $0.00 |
DisclosureSEC source: 0000950170-24-077522 · ownership.xml · derivative · entry 14 Brown Ryan Edward · CIK 0001848718 · EVP, General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,500 shares Expires 2028-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 2,549 | $164.52 | $419,361.48 |
DisclosureSEC source: 0000950170-24-077522 · ownership.xml · nonDerivative · entry 10 Brown Ryan Edward · CIK 0001848718 · EVP, General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,129 F3 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2024. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 3,840 | $163.53 | $627,955.20 |
DisclosureSEC source: 0000950170-24-077522 · ownership.xml · nonDerivative · entry 9 Brown Ryan Edward · CIK 0001848718 · EVP, General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,678 F3 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2024. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.19 to $163.98 inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 17,581 | $162.65 | $2,859,549.65 |
DisclosureSEC source: 0000950170-24-077522 · ownership.xml · nonDerivative · entry 8 Brown Ryan Edward · CIK 0001848718 · EVP, General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,518 F3 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2024. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $162.12 to $163.09, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 4,168 | $161.82 | $674,465.76 |
DisclosureSEC source: 0000950170-24-077522 · ownership.xml · nonDerivative · entry 7 Brown Ryan Edward · CIK 0001848718 · EVP, General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,099 F3 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2024. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $161.04 to $162.02, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 975 | $160.31 | $156,302.25 |
DisclosureSEC source: 0000950170-24-077522 · ownership.xml · nonDerivative · entry 6 Brown Ryan Edward · CIK 0001848718 · EVP, General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,267 F3 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2024. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.71 to $160.69, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 2,200 | $159.14 | $350,108.00 |
DisclosureSEC source: 0000950170-24-077522 · ownership.xml · nonDerivative · entry 5 Brown Ryan Edward · CIK 0001848718 · EVP, General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,242 F3 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2024. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.67 to $159.66, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 7,644 | $158.07 | $1,208,287.08 |
DisclosureSEC source: 0000950170-24-077522 · ownership.xml · nonDerivative · entry 4 Brown Ryan Edward · CIK 0001848718 · EVP, General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,442 F3 · shares: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 7, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $157.58 to $158.52, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 23,500 | $62.77 | $1,475,095.00 |
DisclosureSEC source: 0000950170-24-077522 · ownership.xml · nonDerivative · entry 3 Brown Ryan Edward · CIK 0001848718 · EVP, General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,086 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 2,352 | $164.64 | $387,233.28 |
DisclosureSEC source: 0000950170-24-077522 · ownership.xml · nonDerivative · entry 2 Brown Ryan Edward · CIK 0001848718 · EVP, General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,586 F2 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of PSUs granted on March 1, 2024. Read SEC document |
| June 21, 2024 Filed Jun 26, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionPerformance Stock Units · Derivative | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-077522 · ownership.xml · derivative · entry 13 Brown Ryan Edward · CIK 0001848718 · EVP, General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. F1 · derivative.exercise_date: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. F1 · derivative.expiration_date: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. Read SEC document |
| June 21, 2024 Filed Jun 26, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantPerformance Stock Units · Derivative | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-077522 · ownership.xml · derivative · entry 12 Brown Ryan Edward · CIK 0001848718 · EVP, General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,250 Underlying: Common Stock · 6,250 shares Expires not disclosed F1 · derivative.exercise_price: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. F1 · derivative.exercise_date: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. F1 · derivative.expiration_date: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. Read SEC document |
| June 21, 2024 Filed Jun 26, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantPerformance Stock Units · Derivative | 5,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-077522 · ownership.xml · derivative · entry 11 Brown Ryan Edward · CIK 0001848718 · EVP, General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,500 shares Expires not disclosed F10 · derivative.exercise_price: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 7, 2022. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 7, 2025, subject to the Reporting Person continuing to provide service to the Company through such vesting date. F10 · derivative.exercise_date: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 7, 2022. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 7, 2025, subject to the Reporting Person continuing to provide service to the Company through such vesting date. F10 · derivative.expiration_date: Represents the number of shares earned under a PSU award granted to the Reporting Person on March 7, 2022. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of prescribed milestones under the terms of the PSU award. The earned PSUs will vest on March 7, 2025, subject to the Reporting Person continuing to provide service to the Company through such vesting date. Read SEC document |
| June 21, 2024 Filed Jun 26, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 6,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-077522 · ownership.xml · nonDerivative · entry 1 Brown Ryan Edward · CIK 0001848718 · EVP, General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,938 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents the number of shares earned and vested under a performance stock unit ("PSU") award granted to the Reporting Person on March 1, 2024. The number of shares earned is based on the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. The PSUs vested immediately upon the Compensation Committee's determination of the Company's achievement of one of the prescribed milestones under the terms of the PSU. Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 899 | $123.14 | $110,702.86 |
DisclosureSEC source: 0000950170-24-029530 · ownership.xml · nonDerivative · entry 2 Brown Ryan Edward · CIK 0001848718 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,688 F2 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 7, 2022. Read SEC document |
| March 07, 2024 Filed Mar 12, 2024 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 506 | $120.49 | $60,967.94 |
DisclosureSEC source: 0000950170-24-029530 · ownership.xml · nonDerivative · entry 1 Brown Ryan Edward · CIK 0001848718 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,587 F1 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 6, 2023. Read SEC document |
| March 04, 2024 Filed Mar 7, 2024 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 1,734 | $125.32 | $217,304.88 |
DisclosureSEC source: 0000950170-24-027495 · ownership.xml · nonDerivative · entry 1 Brown Ryan Edward · CIK 0001848718 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,093 F1 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 3, 2021. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Option (right to buy) · Derivative | 12,500 | $0.00 Strike: $128.67 | $0.00 |
DisclosureSEC source: 0000950170-24-026609 · ownership.xml · derivative · entry 4 Brown Ryan Edward · CIK 0001848718 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2034-03-01 F4 · derivative.exercise_date: Represents the date upon which the first 25% of the option granted vests. 1/48th of the total granted option vests and become exercisable on each monthly anniversary thereafter. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 2,000 | $125.34 | $250,680.00 |
DisclosureSEC source: 0000950170-24-026609 · ownership.xml · nonDerivative · entry 3 Brown Ryan Edward · CIK 0001848718 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,827 F3 · shares: Represents a sale of shares of common stock to generate cash for the payment of taxes due as a result of the vesting of certain restricted stock unit awards. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-026609 · ownership.xml · nonDerivative · entry 2 Brown Ryan Edward · CIK 0001848718 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,827 F2 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest on the first anniversary of the grant date, and additional 25% will vest on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested on the fourth anniversary of the grant date. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 269 | $126.19 | $33,945.11 |
DisclosureSEC source: 0000950170-24-026609 · ownership.xml · nonDerivative · entry 1 Brown Ryan Edward · CIK 0001848718 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,827 F1 · shares: Shares were sold by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on February 28, 2020. Read SEC document |
| June 01, 2023 Filed Jun 6, 2023 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 89 | $123.60 | $11,000.40 |
DisclosureSEC source: 0001209191-23-034676 · doc4.xml · nonDerivative · entry 1 Brown Ryan Edward · CIK 0001848718 · EVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,096 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on May 31, 2019. Read SEC document |
| March 08, 2023 Filed Mar 11, 2023 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 635 | $153.19 | $97,275.65 |
DisclosureSEC source: 0001209191-23-018019 · doc4.xml · nonDerivative · entry 1 Brown Ryan Edward · CIK 0001848718 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,185 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 7, 2022. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $155.99 | $0.00 |
DisclosureSEC source: 0001209191-23-017400 · doc4.xml · derivative · entry 4 Brown Ryan Edward · CIK 0001848718 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2033-03-06 F4 · derivative.exercise_date: Represents the date upon which the first 25% of the option granted vests. 1/48th of the total granted option vests and become exercisable on each monthly anniversary thereafter. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-017400 · doc4.xml · nonDerivative · entry 3 Brown Ryan Edward · CIK 0001848718 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,820 F3 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest on the first anniversary of the grant date, and additional 25% will vest on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested on the fourth anniversary of the grant date. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 171 | $157.21 | $26,882.91 |
DisclosureSEC source: 0001209191-23-017400 · doc4.xml · nonDerivative · entry 2 Brown Ryan Edward · CIK 0001848718 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,320 F2 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 4, 2019. Read SEC document |
| March 06, 2023 Filed Mar 9, 2023 01:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 1,154 | $157.21 | $181,420.34 |
DisclosureSEC source: 0001209191-23-017400 · doc4.xml · nonDerivative · entry 1 Brown Ryan Edward · CIK 0001848718 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,491 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 3, 2021. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 01:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 196 | $147.57 | $28,923.72 |
DisclosureSEC source: 0001209191-23-016057 · doc4.xml · nonDerivative · entry 1 Brown Ryan Edward · CIK 0001848718 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,645 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on 02/28/2020. Read SEC document |
| June 01, 2022 Filed Jun 4, 2022 00:00 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 54 | $72.67 | $3,924.18 |
DisclosureSEC source: 0001209191-22-034380 · doc4.xml · nonDerivative · entry 1 Brown Ryan Edward · CIK 0001848718 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,841 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on May 31, 2019. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 01:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Option (right to buy) · Derivative | 48,000 | $0.00 Strike: $80.42 | $0.00 |
DisclosureSEC source: 0001209191-22-017346 · doc4.xml · derivative · entry 4 Brown Ryan Edward · CIK 0001848718 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 Underlying: Common Stock · 48,000 shares Expires 2032-03-07 F4 · derivative.exercise_date: Represents the date upon which the first 25% of the option granted vests. 1/48th of the total granted option vests and become exercisable on each monthly anniversary thereafter. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 01:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-017346 · doc4.xml · nonDerivative · entry 3 Brown Ryan Edward · CIK 0001848718 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,895 F3 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest on the first anniversary of the grant date, and additional 25% will vest on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested on the fourth anniversary of the grant date. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 01:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 153 | $79.36 | $12,142.08 |
DisclosureSEC source: 0001209191-22-017346 · doc4.xml · nonDerivative · entry 2 Brown Ryan Edward · CIK 0001848718 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,895 F2 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 4, 2019. Read SEC document |
| March 04, 2022 Filed Mar 9, 2022 01:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 1,136 | $79.20 | $89,971.20 |
DisclosureSEC source: 0001209191-22-017346 · doc4.xml · nonDerivative · entry 1 Brown Ryan Edward · CIK 0001848718 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,048 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 3, 2021. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 01:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 184 | $75.05 | $13,809.20 |
DisclosureSEC source: 0001209191-22-014407 · doc4.xml · nonDerivative · entry 1 Brown Ryan Edward · CIK 0001848718 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,184 F1 · shares: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on February 28, 2020. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 20:57 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 64 | $76.01 | $4,864.64 |
DisclosureSEC source: 0001209191-21-037727 · doc4.xml · nonDerivative · entry 1 Brown Ryan Edward · CIK 0001848718 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,368 F1 · kind: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on May 31, 2019. Read SEC document |
| March 04, 2021 Filed Mar 11, 2021 01:01 UTC Amendment | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 190 | $80.76 | $15,344.40 |
DisclosureSEC source: 0001209191-21-019667 · doc4a.xml · nonDerivative · entry 3 Brown Ryan Edward · CIK 0001848718 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,432 F3 · kind: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 4, 2019. Read SEC document |
| March 03, 2021 Filed Mar 6, 2021 01:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $87.11 | $0.00 |
DisclosureSEC source: 0001209191-21-018414 · doc4.xml · derivative · entry 2 Brown Ryan Edward · CIK 0001848718 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2031-03-03 F2 · derivative.exercise_date: Represents the date upon which the first 25% of the option granted vests. 1/48th of the total granted option vests and become exercisable on each monthly anniversary thereafter. Read SEC document |
| March 03, 2021 Filed Mar 6, 2021 01:02 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018414 · doc4.xml · nonDerivative · entry 1 Brown Ryan Edward · CIK 0001848718 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,838 F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest and become exercisable on the first anniversary of the grant date, and additional 25% will vest and become exercisable on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested and exercisable on the fourth anniversary of the grant date. Read SEC document |
| March 03, 2021 Filed Mar 11, 2021 01:01 UTC Amendment | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-019667 · doc4a.xml · nonDerivative · entry 2 Brown Ryan Edward · CIK 0001848718 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,622 F2 · balance_after: On March 5, 2021, the Form 4 filed for the reporting person overstated the number of shares held by the reporting person. This amended form corrects such error by reporting the number of shares withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units on February 28, 2021 and by reporting the corrected total amount of securities directly owned by the reporting person following a grant of restricted stock units on March 3, 2021. Read SEC document |
| February 28, 2021 Filed Mar 11, 2021 01:01 UTC Amendment | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Tax withholdingCommon Stock | 216 | $86.97 | $18,785.52 |
DisclosureSEC source: 0001209191-21-019667 · doc4a.xml · nonDerivative · entry 1 Brown Ryan Edward · CIK 0001848718 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,622 F1 · kind: Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on February 28, 2020. F2 · balance_after: On March 5, 2021, the Form 4 filed for the reporting person overstated the number of shares held by the reporting person. This amended form corrects such error by reporting the number of shares withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units on February 28, 2021 and by reporting the corrected total amount of securities directly owned by the reporting person following a grant of restricted stock units on March 3, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.